Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hydrocortisone - Diurnal

Drug Profile

Hydrocortisone - Diurnal

Alternative Names: Alkindi; ALKINDI SPRINKLE; Chronocort; DNL-0200; Efmody; EFMODY; Hydrocortisone extended release - Diurnal; Infacort; Modified-release hydrocortisone

Latest Information Update: 19 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Diurnal
  • Developer Diurnal; EffRx; Emerge Health; Eton Pharmaceuticals; Medison Pharma
  • Class Anti-inflammatories; Antiallergics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Congenital adrenal hyperplasia; Adrenal insufficiency
  • New Molecular Entity No

Highest Development Phases

  • Marketed Adrenal insufficiency; Congenital adrenal hyperplasia

Most Recent Events

  • 15 Jun 2023 The European Commission approves a MAA for Congenital adrenal hyperplasia in EU
  • 15 Jun 2023 The Medicines and Healthcare products Regulatory Agency (MHRA) approves a Marketing Authorization application (MAA) for Congenital adrenal hyperplasia in UK
  • 29 May 2023 EffRx has been acquired by Abiogen Pharma
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top